Welcome to our dedicated page for Affimed SEC filings (Ticker: AFMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Affimed N.V. (AFMD) SEC filings page on Stock Titan provides access to the company’s historical regulatory documents, including the Form 25 that removed its common stock from listing and registration on The Nasdaq Stock Market LLC. This Form 25, filed in July 2025, identifies Affimed N.V. as the issuer and Nasdaq Stock Market LLC as the exchange, and confirms that the company’s common stock has been struck from listing under Section 12(b) of the Securities Exchange Act of 1934.
Filings for AFMD are particularly relevant for understanding the company’s transition from a Nasdaq-listed, clinical-stage immuno-oncology issuer into insolvency proceedings in Germany and subsequent delisting. Earlier periodic and current reports (where available) can provide background on Affimed’s innate cell engager (ICE®) platform, its clinical-stage pipeline in hematologic and solid tumors, and risk factor disclosures related to funding, going-concern considerations, and operational challenges.
On this page, investors and researchers can review key SEC forms such as annual and quarterly reports (Forms 10-K and 10-Q, if filed), current reports on Form 8-K describing material events, and the Form 25 that documents the delisting of AFMD from Nasdaq. These documents help explain how Affimed described its ICE® programs, including AFM24 and AFM28, its ROCK® platform, and the financial and regulatory context leading up to the insolvency filings in Mannheim, Germany.
Stock Titan enhances this information by pairing EDGAR-sourced filings with AI-powered summaries that highlight important sections and clarify complex regulatory language. Users can quickly identify discussions of liquidity, going-concern warnings, clinical program updates, and listing status changes without reading every page. Real-time updates from EDGAR ensure that any new or amended filings for AFMD are reflected promptly, while historical filings remain available for those analyzing Affimed’s full regulatory history.
Nasdaq Stock Market LLC has filed Form 25 to strike Affimed N.V. (AFMD) common stock from listing and registration under Section 12(b) of the Exchange Act. The notification, signed on 2025-07-21 by a Nasdaq hearings advisor, states that the exchange believes it meets all regulatory requirements for delisting. No financial results, trading data, or rationale are provided in the filing.
The action will remove AFMD from the Nasdaq Global Market once the SEC’s 10-day period elapses, and registration under Section 12(g) will be terminated after 90 days unless the company files contrary documentation. Investors should anticipate the stock moving to an over-the-counter venue or another exchange, subject to separate listing standards.